 - All patients must receive multi-agent based chemotherapy, preferably VAD, as cytoreduction prior to transplantation. The time from the last chemotherapy administration must be greater than 21 days. Patients with recurrent myeloma must have sensitive disease as demonstrated by a decrease in serum or urine paraprotein levels of 50 or a decrease in bone marrow plasmacytosis to less than 20. Patients with newly diagnosed myeloma may have stable but not progressive disease following VAD. 